BSECOLINZ LABORATORIES LTD.· Pharmaceuticals & BiotechnologyHighNeutral
Announced Thu, 30 Jul, 2026 · 17:42 IST

Q1 FY27 results: PAT jumps to Rs 240.12 lakh on Rs 276 lakh asset sale gain

Revenue DeclineExceptional ItemResults View source PDFExplain this filing

Price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close
+2.5%Reaction day
₹80.00
prior close
—
announcement price
After-mkt
timing
Nifty Microcap 250market · in no size index; the smallest one is used+1.1%+1.4% vs market
Pharmaceuticals peers, median of 164sector+0.1%+2.4% vs sector

On the reaction day the stock moved 1.4 pts more than Nifty Microcap 250 and 2.4 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark
Stock
5m
—
10m
—
15m
—
30m
—
Sessions after the filingfrom the prior close
StockMarketvs marketSectorvs sector
Reaction day
+2.5+1.1+1.4+0.1+2.4
Next day
+0.6+2.4-1.8+1.1-0.5
2d
-2.5+2.9-5.4+1.0-3.5
3d
+2.1+4.2-2.1+1.1+1.0
4d
+2.5+4.6-2.1+1.2+1.3
5d
+4.3+4.6-0.4+1.4+2.8
1w
-0.6+4.4-5.0+2.3-2.9
15d
-5.0+5.7-10.7+1.3-6.3
1m
-7.6+6.6-14.2+2.3-9.9
2m
-4.1+5.4-9.5+3.2-7.3
3m
—————
UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 164Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Board approved Q1 FY27 unaudited results. Revenue from operations fell to Rs 124.09 lakh from Rs 156.61 lakh YoY, a drop of about 21 percent. PAT surged to Rs 240.12 lakh versus Rs 11.92 lakh, driven by an exceptional gain of Rs 276.33 lakh from sale of factory land, building and machinery at Sinnar. CEO N.K. Menon reappointed for one more year. AGM set for 22 September 2026.

Likely market impact

Core revenue is down about 21% YoY. Headline PAT jump is a one-time asset sale windfall, not from operations.